Skip to main content
. 2024 Oct 15;14(10):4817–4829. doi: 10.62347/JKTJ7904

Figure 2.

Figure 2

Higher expression of EIF3M conferred poor prognosis in LUAD. Survival analysis as overall survival (OS) and relapse-free survival (RFS) in LUAD (A) and LUSC (B) using Kaplan-Meier survival analysis. The protein expression of eIF3m in primary tumor tissue, tumor grades, and cancer stages in LUAD from CPTAC dataset (C). The expression of EIF3M in the tumor part of NSCLC_EMTAB6149 from the TISCH2 (D). Immunohistochemical staining of eIF3m from in-house LUAD patients (E). *, P < 0.05; ****, P < 0.001; na = not applicable.